At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women With Newly Diagnosed, Previously Untreated, Gynaecological Tumors
In Brief
A Phase 2 clinical trial evaluating pazopanib (GW786034), carboplatin, and 1 other intervention for Primary Peritoneal Carcinoma and 6 related conditions. Completed, enrolled 12 participants across 5 sites in 2 countries.
Detailed Summary
This is an open-label, two-arm, multicenter feasibility study to evaluate the safety and tolerability of pazopanib in combination with carboplatin and paclitaxel in female subjects with newly diagnosed advanced gynaecological tumors. Subjects will have received no prior therapy for their disease. A minimum of 12 and a maximum of 46 subjects will be enrolled. Dose schemas for each study arm are described in the protocol. For each arm, six subjects will be evaluated in treatment cohorts, which will be expanded to 20 subjects if initial toxicity is acceptable. Overall safety and tolerability of the regimen will be based on dose limiting toxicities, adverse events, and percentage of subjects that complete 6 courses of study treatment. Antitumor activity will be assessed using RECIST criteria and cancer antigen 125 (CA-125) responses.
Study Details
Timeline
Interventions
800 mg orally once a day for 6 cycles
IV over one hour every 3 weeks of 6 cycles
IV 175 mg/m\^2 given over 3 hours on day one of a 21 day cycle for six cycles